Literature DB >> 15695042

Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients.

C Klug1, A Wutzl, C Kermer, M Voracek, G Kornek, E Selzer, C Glaser, P W Poeschl, W Millesi, R Ewers.   

Abstract

To analyse survival and locoregional control in patients with advanced oral and oropharyngeal squamous cell carcinoma (SCC) after multimodal therapy with preoperative radiochemotherapy (RCT) and radical surgery. We included in this analysis 222 patients who underwent multimodal therapy between 1990 and 2000. Eligible were patients with UICC disease stages II-IV (T2: 33.3%; T3: 12.6%; T4: 54.1%; N0: 45.9%; N1: 17.6%; N2: 33.3%; N3: 3.2%; stage II: 21.1%; stage III: 14.9%; stage IV: 64%). Patients received preoperative radiochemotherapy consisting of Mitomycin C (15-20 mg/m2, day 1) plus 5-Fluorouracil (750 mg/m2/24 h-infusion, days 1-5) and concomitant radiotherapy for a total dose of 50 Gy. Radical locoregional en bloc-resection according to the pretherapeutic tumour extension was carried out in all patients. After a median surveillance period of 72.3 months (24-152 months), 131 patients (59%) were alive, and 91 (41%) patients died; 12 (5%) of them died postoperatively, 46 (21%) due to tumour recurrence, and 33 (15%) deaths were not directly related to the primary tumour. Overall survival probability was 76% after 2 years, and 62% after 5 years. Two- and 5-year local control probability were 88 and 81%, respectively. Regarding the high percentage of stage IV disease in the reported patients, the multimodal concept is an effective therapy offering excellent survival and local control probability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695042     DOI: 10.1016/j.ijom.2004.04.003

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  8 in total

1.  Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.

Authors:  Marie Blonski; Luc Taillandier; Guillaume Herbet; Igor Lima Maldonado; Patrick Beauchesne; Michel Fabbro; Chantal Campello; Catherine Gozé; Valérie Rigau; Sylvie Moritz-Gasser; Christine Kerr; Roberta Rudà; Riccardo Soffietti; Luc Bauchet; Hugues Duffau
Journal:  J Neurooncol       Date:  2011-07-22       Impact factor: 4.130

Review 2.  [Plastic reconstruction of radiation injuries].

Authors:  P M Vogt; T R Mett; C Henkenberens; C Radtke; R Ipaktchi
Journal:  Chirurg       Date:  2017-06       Impact factor: 0.955

Review 3.  [Surgical treatment options for squamous cell carcinoma of the oral cavity].

Authors:  Michael Rasse
Journal:  Wien Med Wochenschr       Date:  2008

4.  [Survival improvement of a unicentric overall population in 20 years: 1038 patients with oral and oropharyngeal squamous cell cancer 1983-2004].

Authors:  Adorján F Kovács; Waleed Megahed; Michael Scholz; Robert Sader
Journal:  Mund Kiefer Gesichtschir       Date:  2007-09-25

Review 5.  [Combined modality approaches in the treatment of head and neck cancer patients].

Authors:  C Simon; P K Plinkert
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

6.  Outcome of Neoadjuvant Chemotherapy on Local Recurrence and Distant Metastasis of Oral Squamous Cell Carcinoma: A Retrospective Study.

Authors:  Reza Tabrizi; Ata Garajei; Ehsan Shafie; Samira Jamshidi
Journal:  J Dent (Shiraz)       Date:  2016-09

7.  Prognostic Value of FDG-PET in patients with oropharyngeal carcinoma treated with concurrent chemoradiotherapy.

Authors:  Keisuke Enomoto; Hidenori Inohara; Ichiro Higuchi; Kenichiro Hamada; Yoichiro Tomiyama; Takeshi Kubo; Jun Hatazawa
Journal:  Mol Imaging Biol       Date:  2008-06-05       Impact factor: 3.488

8.  Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting pathological response to preoperative super-selective intra-arterial chemoradiotherapy for advanced squamous cell carcinoma of the mandible.

Authors:  Maiko Shibasaki; Toshinori Iwai; Senri Oguri; Toshiyuki Koizumi; Makoto Hirota; Kenji Mitsudo; Yukihiko Ozawa; Iwai Tohnai
Journal:  J Bone Oncol       Date:  2018-02-07       Impact factor: 4.072

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.